Skip to main content
. 2022 Dec 1;45(2):797–809. doi: 10.1007/s11357-022-00697-y

Table 3.

Baseline characteristics of the population according to IL-6 and TNFR1 levels (median)

Variables
n (%) or median (IQR)
IL-6 Low levels (N = 548) IL-6 High levels (N = 546) p-value TNFR1 Low levels (N = 547) TNFR1 high levels (N = 545) p-value
Age (years) 74 (71–77) 76 (72–79)  < 0.001 73 (71–77) 76 (72–79)  < 0.001
Gender. male 180 (32.8) 215 (39.3) 0.02 168 (30.7) 227 (41.6)  < 0.001
BMI (kg/m2) 24.8 (22.7–27.5) 26.5 (23.7–29.3)  < 0.001 24.8 (22.6–27.5) 26.5 (23.8–29.2)  < 0.001
MAPT group:
  PUFA + MI 142 (25.9) 132 (24.2) 138 (25.2) 135 (24.8)
  PUFA 144 (26.3) 122 (22.3) 0.19 143 (26.1) 124 (22.7)  0.464
  MI 125 (22.8) 151 (27.7) 136 (24.9) 138 (25.3)
  Control 137 (25.0) 141 (25.8) 130 (23.8) 148 (27.2)
Asthma/COPD 37 (6.7) 40 (7.3) 0.71 38 (6.9) 38 (6.9) 0.98
Stroke 11 (2.0) 12 (2.1) 0.82 14 (2.5) 9 (1.6) 0.29
Active cancer 21 (3.8) 17 (3.1) 0.51 18 (3.2) 20 (3.6) 0.73
IHD 25 (4.5) 42 (7.6) 0.03 26 (4.7) 41 (7.5) 0.05
Diabetes 39 (7.1) 67 (12.2)  < 0.01 39 (7.1) 66 (12.1)  < 0.01
Heart failure 6 (1.0) 11 (2.0) 0.21 5 (0.9) 11 (2.0) 0.12
Atrial fibrillation 14 (2.5) 25 (4.5) 0.07 19 (3.4) 38 (6.9) 0.99
Antyhypertensives 243 (44.3) 310 (56.7)  < 0.001 226 (41.3) 323 (59.2)  < 0.001
CKD 87 (15.9) 108 (19.7) 0.09 58 (10.6) 133 (24.4)  < 0.001
Systolic blood pressure (mmHg)
  Baseline mean 134.7 (126.5–143.2) 136.4 (128.3–146.5)  < 0.01 134.8 (127.0–143.6) 136.5 (127.5–146) 0.06
  SBPV:
    SD 11.3 (8.3–14.1) 11.8 (8.7–15.4) 0.02 11.4 (8.3–14.7) 11.8 (8.6–15.2) 0.07
    CV% 8.3 (6.1–10.8) 8.7 (6.5–11.0) 0.10 8.4 (6.1–10.7) 8.7 (6.5–11.1) 0.15
    VIM 11.4 (8.4–14.8) 11.9 (9.0–15.1) 0.17 11.6 (8.4–14.6) 11.7 (9.0–15.2) 0.18
    RSD 17.7 (13.8–23.7) 18.7 (14.0–25.6) 0.06 17.6 (13.6–23.6) 18.8 (14.0–25.8) 0.02
    ARV 12.3 (8.6–16.6) 13.0 (9.3–18.0) 0.01 12.6 (8.6–16.6) 12.6 (9.3–18.0) 0.10
    SV 14.9 (10.5–20.1) 15.7 (11.3–20.9) 0.03 15.3 (10.6–20.2) 15.4 (11.1–20.7) 0.18
Diastolic blood pressure (mmHg)
  Baseline mean 75.7 (70.5–81.5) 76.3 (70.8–81.4) 0.46 76.4 (71.7–81.6) 76.0 (70.0–81.42) 0.12
  DBPV:
    SD 7.3 (5.5–9.5) 7.5 (5.6–9.9) 0.33 7.4 (5.5–9.9) 7.4 (5.6–9.7) 0.63
    CV% 9.8 (7.2–12.4) 9.7 (7.4–13.0) 0.50 9.8 (7.3–12.7) 9.7 (7.4–12.7) 0.90
    VIM 7.4 (5.6–9.4) 7.5 (5.6–9.9) 0.42 7.5 (5.6–9.8) 7.4 (5.6–9.7) 0.78
    RSD 11.6 (8.7–15.1) 12.2 (9.0–15.3) 0.24 11.8 (8.9–15.1) 11.9 (8.7–15.2) 0.88
    ARV 8.1 (5.6–10.6) 8.1 (6.0–11.2) 0.27 8.1 (6.0–10.8) 8.1 (5.6–11.0) 0.71
    SV 9.8 (7.2–12.8) 10.0 (7.4–13.3) 0.43 9.8 (7.3–13.0) 9.9 (7.0–13.0) 0.60

ARV, average real variability; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, coefficient of variation; IHD, ischemic heart disease; MI, multidomain intervention; PUFA, omega-3 polyunsaturated fatty acid supplementation; RSD, residual standard deviation; SD, standard deviation; SV, successive variation; VIM, variation independent of mean

High and low levels of IL-6 and TNFR1 were identified according to the median values (2.57 pg/mL and 1141 pg/mL respectively), after removing outliers